Preview

Pediatric pharmacology

Advanced search

Vaccinal Prevention of Pneumococcal Infection in Children

https://doi.org/10.15690/pf.v12i5.1457

Abstract

It is known that before vaccination had been widely introduced pneumococcal infection was the cause of death of more than 1.5 mn people around the world annually, 40% of whom were infants. According to the World Health Organization (WHO), pneumococcal infection is the most dangerous of the vaccinally prevented diseases. Resistance of pneumococcus to antibacterial drugs is a global issue complicating control of pneumococcal infection around the world. Increasing resistance of the causative agent complicates treatment of patients with various forms of pneumococcal diseases, requires use of the second- and the third-line therapeutic antimicrobial drugs and increases duration of hospitalization and treatment costs. Vaccination is considered the main method of preventing antibiotic-resistant pneumococcus-induced infections. The authors present the newest opinions on vaccinal prevention of pneumococcus-induced diseases. 

About the Authors

A. A. Baranov
Scientific Center of Children’s Health of the Ministry of Health of Russia, Moscow, Russian Federation Sechenov First Moscow State Medical University, Moscow, Russian Federation
Russian Federation


L. S. Namazova-Baranova
Scientific Center of Children’s Health of the Ministry of Health of Russia, Moscow, Russian Federation Sechenov First Moscow State Medical University, Moscow, Russian Federation Pirogov Russian National Medical Research University, Moscow, Russian Federation
Russian Federation


N. I. Briko
Scientific Center of Children’s Health of the Ministry of Health of Russia, Moscow, Russian Federation Sechenov First Moscow State Medical University, Moscow, Russian Federation
Russian Federation


Y. V. Lobzin
Federal State Institution “Research Institute of Pediatric Infections” of the Federal Biomedical Agency, Saint Petersburg, Russian Federation
Russian Federation


V. K. Tatochenko
Scientific Center of Children’s Health of the Ministry of Health of Russia, Moscow, Russian Federation
Russian Federation


S. M. Kharit
Federal State Institution “Research Institute of Pediatric Infections” of the Federal Biomedical Agency, Saint Petersburg, Russian Federation
Russian Federation


M. V. Fedoseyenko
Scientific Center of Children’s Health of the Ministry of Health of Russia, Moscow, Russian Federation Sechenov First Moscow State Medical University, Moscow, Russian Federation
Russian Federation


E. A. Vishnyova
Scientific Center of Children’s Health of the Ministry of Health of Russia, Moscow, Russian Federation
Russian Federation


L. R. Selimzyanova
Scientific Center of Children’s Health of the Ministry of Health of Russia, Moscow, Russian Federation Sechenov First Moscow State Medical University, Moscow, Russian Federation
Russian Federation


References

1. Пневмококковые вакцины: документ по позиции ВОЗ, 2012 год. Еженедельный бюллетень, 6 апреля 2012 г., 87-й год No 14. 2012;87:129–144. URL: http://www.who.int/immunization/ position_papers/WHO_PP_pneumococcal_2012_RU.pdf

2. Баранов АА, Намазова-Баранова ЛС, Маянский НА, Куличенко ТВ, Полунина ТА, Лазарева АВ, Алябьева НМ, Катосова ЛК, Пономаренко ОА, Колтунов ИЕ, Иваненко АМ, Дегтярева ЕА, Кондратенко НВ, Корсунский АА, Константинов КВ, Тулупов ДА, Лазарева МА. Роль Streptococcus pneumoniae в структуре бактериальных инфекций у детей, госпитализированных в стационары г. Москвы в 2011–201 гг. Педиатрическая фармакология. 2013;10(5):6–12.

3. Козлов РС, Кречикова ОИ, Муравьев АА, Миронов КО, Платонов АЕ, Дунаева ЕА, Таточенко ВК, Щербаков МЕ, Родникова ВЮ, Романенко ВВ, Сафьянов КН. Результаты исследования распространенности в России внебольничной пневмонии и острого среднего отита у детей в возрасте до 5 лет (PAPIRUS). Роль S. pneumoniae и H. influenzae в этиологии данных заболеваний. Клиническая микробиология и антимикробная химиотерапия. 2013;15(4):246–260.

4. Bocchini JA. Jr. et al. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics. 2010;126:186–190.

5. Johnson HL. et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Medicine. 2010,7: e1000348.

6. Russel F. et al. 2011. Global review of the distribution of pneumococcal disease by age and region. SAGE meeting, 8–10 November 2011. URL: http://www.who.int/immunization/ sage/6_Russel_review_age_specific_epidemiology_PCV_ schedules_session_ nov11.pdf, accessed March 2012.

7. DeStefano F. et al. Safety profile of pneumococcal conjugate vaccines: systematic review of preand postlicensure data. Bulletin of the World Health Organization. 2008;86:373–380.

8. Эпидемиология и вакцинопрофилактика инфекции, вызываемой Streptococcus pneumoniae. Методические рекомендации МР 3.3.1.0027–11 (утв. Федеральной службой по надзору в сфере защиты прав потребителей и благополучия человека 20 июля 2011 г.). М., 2011.

9. Сидоренко СВ, Лобзин ЮВ, Харит СМ, Королева ИС, Таточенко ВК. Пневмококковая инфекция и возможности ее профилактики — эпидемиологический обзор ситуации в мире и в России. Вопросы современной педиатрии. 2010;9(1):54–61. 10. Рекомендации расширенного заседания Совета экспертов на тему «Бремя пневмококковых заболеваний в России». Вопросы современной педиатрии. 2009;8(2):104–108.


Review

For citations:


Baranov A.A., Namazova-Baranova L.S., Briko N.I., Lobzin Y.V., Tatochenko V.K., Kharit S.M., Fedoseyenko M.V., Vishnyova E.A., Selimzyanova L.R. Vaccinal Prevention of Pneumococcal Infection in Children. Pediatric pharmacology. 2015;12(5):550-558. (In Russ.) https://doi.org/10.15690/pf.v12i5.1457

Views: 1169


ISSN 1727-5776 (Print)
ISSN 2500-3089 (Online)